Report cover image

Opioid Receptor Agonist Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 137 Pages
SKU # APRC20352299

Description

Summary

According to APO Research, the global Opioid Receptor Agonist market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Opioid Receptor Agonist is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Opioid Receptor Agonist is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Opioid Receptor Agonist is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Opioid Receptor Agonist include Allergan, DAIICHI SANKYO COMPANY, Endo Pharmaceuticals, Fresenius Kabi, Hikma Pharmaceuticals, Indivior, Mylan N.V., Piramal Critical Care and Purdue Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Opioid Receptor Agonist, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Opioid Receptor Agonist.

The report will help the Opioid Receptor Agonist manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Opioid Receptor Agonist market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Opioid Receptor Agonist market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Opioid Receptor Agonist Segment by Company

Allergan
DAIICHI SANKYO COMPANY
Endo Pharmaceuticals
Fresenius Kabi
Hikma Pharmaceuticals
Indivior
Mylan N.V.
Piramal Critical Care
Purdue Pharma
Sun Pharmaceutical Industries
Tris Pharma
US WorldMeds
Pfizer
Johnson & Johnson
Teva Pharmaceutical Industries
Opioid Receptor Agonist Segment by Type

Morphine
Codeine
Fentanyl
Others
Opioid Receptor Agonist Segment by Application

Retail Pharmacy
Online Pharmacy
Hospital Pharmacy
Opioid Receptor Agonist Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Receptor Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Opioid Receptor Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Receptor Agonist.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Opioid Receptor Agonist manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Opioid Receptor Agonist by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Opioid Receptor Agonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

137 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Opioid Receptor Agonist Market Size (2020-2031)
2.2.2 Global Opioid Receptor Agonist Sales (2020-2031)
2.2.3 Global Opioid Receptor Agonist Market Average Price (2020-2031)
2.3 Opioid Receptor Agonist by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Morphine
2.3.3 Codeine
2.3.4 Fentanyl
2.3.5 Others
2.4 Opioid Receptor Agonist by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacy
2.4.4 Hospital Pharmacy
3 Market Competitive Landscape by Manufacturers
3.1 Global Opioid Receptor Agonist Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Opioid Receptor Agonist Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Opioid Receptor Agonist Revenue of Manufacturers (2020-2025)
3.4 Global Opioid Receptor Agonist Average Price by Manufacturers (2020-2025)
3.5 Global Opioid Receptor Agonist Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Opioid Receptor Agonist, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Opioid Receptor Agonist, Product Type & Application
3.8 Global Manufacturers of Opioid Receptor Agonist, Established Date
3.9 Global Opioid Receptor Agonist Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Allergan
4.1.1 Allergan Company Information
4.1.2 Allergan Business Overview
4.1.3 Allergan Opioid Receptor Agonist Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Allergan Opioid Receptor Agonist Product Portfolio
4.1.5 Allergan Recent Developments
4.2 DAIICHI SANKYO COMPANY
4.2.1 DAIICHI SANKYO COMPANY Company Information
4.2.2 DAIICHI SANKYO COMPANY Business Overview
4.2.3 DAIICHI SANKYO COMPANY Opioid Receptor Agonist Sales, Revenue and Gross Margin (2020-2025)
4.2.4 DAIICHI SANKYO COMPANY Opioid Receptor Agonist Product Portfolio
4.2.5 DAIICHI SANKYO COMPANY Recent Developments
4.3 Endo Pharmaceuticals
4.3.1 Endo Pharmaceuticals Company Information
4.3.2 Endo Pharmaceuticals Business Overview
4.3.3 Endo Pharmaceuticals Opioid Receptor Agonist Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Endo Pharmaceuticals Opioid Receptor Agonist Product Portfolio
4.3.5 Endo Pharmaceuticals Recent Developments
4.4 Fresenius Kabi
4.4.1 Fresenius Kabi Company Information
4.4.2 Fresenius Kabi Business Overview
4.4.3 Fresenius Kabi Opioid Receptor Agonist Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Fresenius Kabi Opioid Receptor Agonist Product Portfolio
4.4.5 Fresenius Kabi Recent Developments
4.5 Hikma Pharmaceuticals
4.5.1 Hikma Pharmaceuticals Company Information
4.5.2 Hikma Pharmaceuticals Business Overview
4.5.3 Hikma Pharmaceuticals Opioid Receptor Agonist Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Hikma Pharmaceuticals Opioid Receptor Agonist Product Portfolio
4.5.5 Hikma Pharmaceuticals Recent Developments
4.6 Indivior
4.6.1 Indivior Company Information
4.6.2 Indivior Business Overview
4.6.3 Indivior Opioid Receptor Agonist Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Indivior Opioid Receptor Agonist Product Portfolio
4.6.5 Indivior Recent Developments
4.7 Mylan N.V.
4.7.1 Mylan N.V. Company Information
4.7.2 Mylan N.V. Business Overview
4.7.3 Mylan N.V. Opioid Receptor Agonist Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Mylan N.V. Opioid Receptor Agonist Product Portfolio
4.7.5 Mylan N.V. Recent Developments
4.8 Piramal Critical Care
4.8.1 Piramal Critical Care Company Information
4.8.2 Piramal Critical Care Business Overview
4.8.3 Piramal Critical Care Opioid Receptor Agonist Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Piramal Critical Care Opioid Receptor Agonist Product Portfolio
4.8.5 Piramal Critical Care Recent Developments
4.9 Purdue Pharma
4.9.1 Purdue Pharma Company Information
4.9.2 Purdue Pharma Business Overview
4.9.3 Purdue Pharma Opioid Receptor Agonist Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Purdue Pharma Opioid Receptor Agonist Product Portfolio
4.9.5 Purdue Pharma Recent Developments
4.10 Sun Pharmaceutical Industries
4.10.1 Sun Pharmaceutical Industries Company Information
4.10.2 Sun Pharmaceutical Industries Business Overview
4.10.3 Sun Pharmaceutical Industries Opioid Receptor Agonist Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Sun Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio
4.10.5 Sun Pharmaceutical Industries Recent Developments
4.11 Tris Pharma
4.11.1 Tris Pharma Company Information
4.11.2 Tris Pharma Business Overview
4.11.3 Tris Pharma Opioid Receptor Agonist Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Tris Pharma Opioid Receptor Agonist Product Portfolio
4.11.5 Tris Pharma Recent Developments
4.12 US WorldMeds
4.12.1 US WorldMeds Company Information
4.12.2 US WorldMeds Business Overview
4.12.3 US WorldMeds Opioid Receptor Agonist Sales, Revenue and Gross Margin (2020-2025)
4.12.4 US WorldMeds Opioid Receptor Agonist Product Portfolio
4.12.5 US WorldMeds Recent Developments
4.13 Pfizer
4.13.1 Pfizer Company Information
4.13.2 Pfizer Business Overview
4.13.3 Pfizer Opioid Receptor Agonist Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Pfizer Opioid Receptor Agonist Product Portfolio
4.13.5 Pfizer Recent Developments
4.14 Johnson & Johnson
4.14.1 Johnson & Johnson Company Information
4.14.2 Johnson & Johnson Business Overview
4.14.3 Johnson & Johnson Opioid Receptor Agonist Sales, Revenue and Gross Margin (2020-2025)
4.14.4 Johnson & Johnson Opioid Receptor Agonist Product Portfolio
4.14.5 Johnson & Johnson Recent Developments
4.15 Teva Pharmaceutical Industries
4.15.1 Teva Pharmaceutical Industries Company Information
4.15.2 Teva Pharmaceutical Industries Business Overview
4.15.3 Teva Pharmaceutical Industries Opioid Receptor Agonist Sales, Revenue and Gross Margin (2020-2025)
4.15.4 Teva Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio
4.15.5 Teva Pharmaceutical Industries Recent Developments
5 Global Opioid Receptor Agonist Market Scenario by Region
5.1 Global Opioid Receptor Agonist Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Opioid Receptor Agonist Sales by Region: 2020-2031
5.2.1 Global Opioid Receptor Agonist Sales by Region: 2020-2025
5.2.2 Global Opioid Receptor Agonist Sales by Region: 2026-2031
5.3 Global Opioid Receptor Agonist Revenue by Region: 2020-2031
5.3.1 Global Opioid Receptor Agonist Revenue by Region: 2020-2025
5.3.2 Global Opioid Receptor Agonist Revenue by Region: 2026-2031
5.4 North America Opioid Receptor Agonist Market Facts & Figures by Country
5.4.1 North America Opioid Receptor Agonist Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Opioid Receptor Agonist Sales by Country (2020-2031)
5.4.3 North America Opioid Receptor Agonist Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Opioid Receptor Agonist Market Facts & Figures by Country
5.5.1 Europe Opioid Receptor Agonist Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Opioid Receptor Agonist Sales by Country (2020-2031)
5.5.3 Europe Opioid Receptor Agonist Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.5.9 Nordic Countries
5.6 Asia Pacific Opioid Receptor Agonist Market Facts & Figures by Country
5.6.1 Asia Pacific Opioid Receptor Agonist Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Opioid Receptor Agonist Sales by Country (2020-2031)
5.6.3 Asia Pacific Opioid Receptor Agonist Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Opioid Receptor Agonist Market Facts & Figures by Country
5.7.1 South America Opioid Receptor Agonist Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Opioid Receptor Agonist Sales by Country (2020-2031)
5.7.3 South America Opioid Receptor Agonist Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Opioid Receptor Agonist Market Facts & Figures by Country
5.8.1 Middle East and Africa Opioid Receptor Agonist Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Opioid Receptor Agonist Sales by Country (2020-2031)
5.8.3 Middle East and Africa Opioid Receptor Agonist Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Opioid Receptor Agonist Sales by Type (2020-2031)
6.1.1 Global Opioid Receptor Agonist Sales by Type (2020-2031) & (K Units)
6.1.2 Global Opioid Receptor Agonist Sales Market Share by Type (2020-2031)
6.2 Global Opioid Receptor Agonist Revenue by Type (2020-2031)
6.2.1 Global Opioid Receptor Agonist Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Opioid Receptor Agonist Revenue Market Share by Type (2020-2031)
6.3 Global Opioid Receptor Agonist Price by Type (2020-2031)
7 Segment by Application
7.1 Global Opioid Receptor Agonist Sales by Application (2020-2031)
7.1.1 Global Opioid Receptor Agonist Sales by Application (2020-2031) & (K Units)
7.1.2 Global Opioid Receptor Agonist Sales Market Share by Application (2020-2031)
7.2 Global Opioid Receptor Agonist Revenue by Application (2020-2031)
7.2.1 Global Opioid Receptor Agonist Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Opioid Receptor Agonist Revenue Market Share by Application (2020-2031)
7.3 Global Opioid Receptor Agonist Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Opioid Receptor Agonist Value Chain Analysis
8.1.1 Opioid Receptor Agonist Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Opioid Receptor Agonist Production Mode & Process
8.2 Opioid Receptor Agonist Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Opioid Receptor Agonist Distributors
8.2.3 Opioid Receptor Agonist Customers
9 Global Opioid Receptor Agonist Analyzing Market Dynamics
9.1 Opioid Receptor Agonist Industry Trends
9.2 Opioid Receptor Agonist Industry Drivers
9.3 Opioid Receptor Agonist Industry Opportunities and Challenges
9.4 Opioid Receptor Agonist Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.